1 Investigating Causal Relationships between Inflammatory Bowel Disease and

2 Autism Spectrum Disorder: A Bidirectional Two-sample Mendelian

3 Randomization Study

- 4 Ruijie Zeng, MBBS^{†1,2}, Rui Jiang, BS^{†1,3}, Jinghua Wang, MD^{†1,4}, Jie Yang, MS¹, Huihuan Wu,
- 5 MBBS^{1,3}, Zewei Zhuo, BS^{1,5}, Qi Yang, BS¹, Jingwei Li, MS¹, Songyan Liao, PhD^{6,7}, Hung-Fat
- 6 Tse, MD, PhD^{*6,7}, Weihong Sha, MD^{*1,8,3,5}, Hao Chen, MD^{*1,8,3,5}
- 7 ¹ Department of Gastroenterology, Guangdong Provincial People's Hospital, Guangdong
- 8 Academy of Medical Sciences, Guangzhou 510080, China
- 9 ² Shantou University Medical College, Shantou 515000, Guangdong, China
- ³ School of Medicine, South China University of Technology, Guangzhou 510006, China
- ⁴ Department of Hematology, Guangdong Provincial People's Hospital, Guangdong Academy
- 12 of Medical Sciences, Guangzhou 510080, China
- ⁵ School of Bioscience and Bioengineering, South China University of Technology,
- 14 Guangzhou 510006, China
- ⁶ Department of Medicine, The University of Hong Kong, Hong Kong SAR 999077, China
- ⁷ Shenzhen Institutes of Research and Innovation, The University of Hong Kong, Shenzhen
- 17 518000, China
- ⁶ The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510515,
- 19 China
- 20 ***Correspondence:**
- 21 Prof. Hung-Fat Tse, Department of Medicine, The University of Hong Kong, Hong Kong SAR

22 999077, China;

23 E-mail: <u>hftse@hku.hk</u>

- 1 Prof. Weihong Sha, Department of Gastroenterology, Guangdong Provincial People's
- 2 Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China;
- 3 E-mail: <u>shaweihong@gdph.org.cn</u>
- 4 Prof. Hao Chen, Department of Gastroenterology, Guangdong Provincial People's Hospital,
- 5 Guangdong Academy of Medical Sciences, Guangzhou 510080, China;
- 6 E-mail: <u>chenhao@gdph.org.cn</u>
- 7 [†]: These authors contributed equally to this work

1 Abstract

2 Background and aims

- 3 Inflammatory bowel disease (IBD) is usually comorbid with psychological disorders.
- 4 Emerging observational studies have indicated the association between autism spectrum
- 5 disorder (ASD) and IBD, including Crohn's disease (CD) and ulcerative colitis (UC), whereas
- 6 the causality remains unknown. Our study aimed to explore the causal association between
- 7 IBD and ASD using bidirectional two-sample Mendelian randomization (MR) design.

8 Methods

- 9 Summary-level data from large-scale genome-wide association (GWAS) studies of IBD
- 10 (International Inflammatory Bowel Disease Genetics Consortium, N_{cases}=25,042,
- 11 N_{controls}=34,915) and ASD (Integrative Psychiatric Research-Psychiatric Genomics
- 12 Consortium, N_{cases}=18,382, N_{controls}=27,969) were retrieved. Gene variants for IBD and ASD
- 13 were selected as instrumental variables. MR analyses were performed mainly including the
- 14 inverse-variance-weighted method with a series of sensitivity tests.

15 Results

- 16 Genetic predisposition to IBD was associated with a high risk of ASD (odds ratio [OR] = 1.03,
- 17 95% confidence interval [CI] = 1.01-1.06, *P* = 0.01; OR [95% CI]: 1.03 [1.01-1.05], *P* = 0.02
- 18 for CD; OR [95% CI]: 1.03 [1.01-1.07], P = 0.04 for UC). In contrast, no causal association
- 19 was found for the genetic liability to ASD on IBD.

20 Conclusions

Our findings reveal that genetically predicted IBD is causally related to ASD, whereas the
 causal association of ASD on IBD is not supported. Our study highlights the early screening

- 1 and surveillance of psychological symptoms, as well as sustaining support for patients with
- 2 IBD. Further investigations on age-specific groups are warranted.

3 Keywords

- 4 Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Autism spectrum disorder,
- 5 Mendelian randomization

1 1. Introduction

Inflammatory bowel disease (IBD), mainly classified into two subtypes including Crohn's
disease (CD) and ulcerative colitis (UC), is a chronic relapsing and remitting disease
contributed by the dysregulated immune system and the commensal ecosystem with no cure
(Graham and Xavier, 2020). Although the incidence of IBD in western countries is relatively
stable, newly industrialized countries are still in the stage of accelerating incidence (Kaplan
and Windsor, 2021).

8 A wide range of comorbid conditions, including metabolic syndrome, cardiovascular 9 disorders, and neuropsychological diseases, have been observed to coexist with IBD (Argollo 10 et al., 2019). Increasing evidence has indicated that poor psychological health might 11 aggravate the disease course of IBD (Fairbrass et al., 2021; Gracie et al., 2016). Autism 12 spectrum disorder (ASD) is a neurodevelopmental disease with impaired social 13 communication skills as well as restricted and repetitive behaviors (American Psychiatric 14 Association and Association, 2013). The suicide attempt and deaths from un-natural causes 15 of patients with ASD are approximately 3-fold higher than the generally population 16 (Catalá-López et al., 2022; Kõlves et al., 2021; Xu et al., 2018). Complex mechanisms 17 including genetic and environmental factors with gene-environment interactions are involved 18 in the development of ASD (Taylor et al., 2020).

Emerging recognition of the associations between IBD and ASD has been raised. Among the patients with IBD, a national Swedish cohort study observes a 40% increased risk of developing ASD (Butwicka et al., 2019). For the patients with ASD, a recent meta-analysis involving over 11 million participants indicates that the risk of subsequently developed IBD is

1 increased by approximately 66% (Kim et al., 2022). Interactions between gut microbiota and 2 the brain also indicate the possible involvement of altered gut microbiome in the 3 pathogenesis of ASD (Bundgaard-Nielsen et al., 2020). The dysregulations in composition, 4 ecology, and functionality of gut microbiome in children with ASD irrespective of diet have been identified (Wan et al., 2022). 5 6 Although increasing evidence has supported the linkages, the causality and sequential 7 temporality between IBD and ASD remains unclear. In this study, using the bidirectional 8 two-sample MR approach (Figure 1), which can avoid confounding, reverse causation, and 9 various biases in observational epidemiological studies (Davey Smith and Hemani, 2014), we 10 aimed to reveal the causal relationship between IBD and ASD. 11 12 2. Methods 13 2.1 Study design 14 A bidirectional two-sample MR design was used to evaluate the causal relationship between 15 IBD and ASD (Figure 1). On the one hand, the causality of IBD on ASD was examined by the 16 MR method. On the other hand, the causality of ASD on IBD was evaluated by the MR 17 method in reverse. This study was based on de-identified summary-level genome-wide 18 association study (GWAS) data, and therefore our study did not require ethical approval or 19 consent.

20

21 2.2 Data sources

22 The summary-level GWAS data of patients with IBD, including UC and CD, was extracted

1	from the study by the International Inflammatory Bowel Disease Genetics Consortium
2	(IIBDGC) (de Lange et al., 2017). The IIBDGC study involves 59,957 individuals (25,042
3	cases and 34,915 controls) for IBD, 40,266 individuals (12,194 cases and 28,072 controls) for
4	CD, and 45,975 individuals (12,366 cases and 33,609 controls) for UC. Summary data of
5	ASD patients were obtained from a study of Integrative Psychiatric Research-Psychiatric
6	Genomics Consortium (iPSYCH-PGC) (Grove et al., 2019). The iPSYCH-PGC study includes
7	46,351 individuals (18,382 cases and 27,969 controls) with ASD. All of the patients and
8	control subjects for IBD and ASD were of European ancestry.

9

10 **2.3 Mendelian randomization analysis**

11 MR was performed in R (V 4.1.0) using the TwoSampleMR package (Hemani et al., 2018). 12 The genetic instruments were selected based on the genome-wide significance threshold (P $< 5 \times 10^{-8}$) associated with each trait, and further underwent the clumping process using a 13 threshold of $r^2 < 0.001$ and distance (kb) = 10 000 of linkage disequilibrium (LD). After 14 15 harmonizing the exposure and outcome datasets, palindromic SNPs with intermediate allele 16 frequencies were removed. If the SNP was not identified in the outcome dataset, a proxy 17 single nucleotide polymorphism (SNP; $r^2 > 0.8$) was utilized, or the SNP was discarded when 18 no proxy was available. F statistics for each instrument were estimated by $F = \beta^2/SE^2$, and an 19 F statistic < 10 was regarded as insufficiently informative for further analysis (Li and Martin, 20 2002). Inverse variance weighted (IVW) regression was principally chosen for inferring 21 causality, assuming all genetic variants were valid instruments (Burgess et al., 2013).

22

1 **2.4 Sensitivity analysis**

2 Heterogeneity was further evaluated using Cochran's Q test and the I² index, and it was 3 considered existing using the criteria of Cochran's Q test's P < 0.05 and $I^2 > 50\%$. The causal 4 effects were further assessed by the MR-Egger, weighted-median (WM), and weighted 5 mode-based estimate (WMBE) methods. MR-Egger intercept and Mendelian Randomization 6 Pleiotropy Residual Sum and Outlier (MR-PRESSO) tests were used to detect potential 7 horizontal pleiotropy (Verbanck et al., 2018). MR-PRESSO was also used to identify 8 horizontal pleiotropic outliers. Leave-one-out analysis was performed to identify potential 9 outliers affecting the overall estimates by excluding one SNP at a time. The causality was 10 established when the following criteria were met: IVW passed the statistical significance (P <11 0.05) and one of the following assumptions was achieved: 1) no detected heterogeneity, 12 and MR-Egger, WM, and WMBE were directionally identical; 2) if heterogeneity was detected, 13 it could be corrected by MR-PRESSO, while less than 50% of the instruments were outliers; 3) 14 heterogeneity existed with more than 50% of the instruments detected as outliers, while 15 results from MR Egger and WM were significant and directionally identical, with WMBE in the 16 same direction (Marini et al., 2020; Verbanck et al., 2018).

17

18 3. Results

19 **3.1 Selection of instrumental variables (IVs)**

LD-independent SNPs for IBD were obtained following the clumping, and the following conditions were used to further remove the listed SNPs: 1) a desired SNP was not detected during extracting SNPs from the outcomes, and a proxy in LD could not be identified from the

outcome; 2) for ambiguous SNPs or palindromic SNPs with ambiguous strands, no correction
could be made. Supplementary Table S2 lists the SNPs selected as IV for further analysis. *F*statistics for each IV-exposure association were larger than 10 (ranging from 29.80 to 500.60).
Thus, the weak instrumental variable bias was less likely to exist in our study.

6 **3.2 Two-sample Mendelian randomization analysis for causality of IBD on ASD**

7 The estimates of causal effect of IBD on ASD were summarized in Figure 2 and 8 Supplementary Figure S1. Table 1 illustrates the results from the examination of 9 heterogeneity. Genetic liability to IBD was significantly associated with an increased risk of 10 ASD, and no outlier was detected by MR-PRESSO test (Inverse variance weighted [IVW, 95% 11 CI]: 1.03 [1.01-1.06], P = 0.01; all results from the methods were directionally consistent; 12 Figure 2, Table 1, Supplementary Figure 1A). Scatter plot was also used to demonstrate 13 the estimates of causal effects (Figure 3A). The causal estimate of IBD on ASD was without 14 heterogeneity (Cochran's Q = 98.10, P = 0.53, Table 1) and remained robust with 15 leave-one-out test (Supplementary Figure S2A). The funnel plots also illustrated that the 16 evidence of heterogeneity for IBD on ASD was not visually significant (Supplementary 17 Figure S3A). No significant evidence of horizontal pleiotropy for the causality of IBD on ASD 18 was found (MR-Egger intercept = -0.002, SE = 0.004, P = 0.54; MR-PRESSO global test P =19 0.56; Supplementary Table S3).

20

3.3 Two-sample Mendelian randomization analysis for causality of CD and UC on ASD
We further evaluated the causal effects of the two IBD subtypes, CD and UC, on ASD.

1	Genetic susceptibility to CD or UC was significantly increased the risk of ASD, and no outlier
2	was detected by MR-PRESSO test (IVW [95% CI]: 1.03 [1.01-1.05], P = 0.02 for CD; IVW [95%
3	CI]: 1.03 [1.01-1.07], P = 0.04 and Weighted median [95% CI]: 1.05 [1.01-1.10], P = 0.04 for
4	UC), all results from the methods were directionally consistent; Figure 2, Table 1,
5	Supplementary Figure 1B-C). Scatter plots were also used to show the estimates of causal
6	effects (Figure 3B-C). The causal estimate of CD or UC on ASD was without heterogeneity
7	(Cochran's Q = 64.43, $P = 0.78$ for CD; Cochran's Q = 62.25, $P = 0.08$ for UC; Table 1). The
8	causality of CD on ASD remained robust (Supplementary Figure S2B), while that of UC on
9	ASD was affected by certain SNPs in leave-one-out tests (Supplementary Figure S2C). The
10	funnel plots were also shown in Supplementary Figure S3B-C. No significant evidence of
11	horizontal pleiotropy for the causal association of CD or UC on ASD was found (MR-Egger
12	intercept = -0.002, SE = -0.005, $P = 0.47$ and MR-PRESSO global test $P = 0.10$ for CD;
13	MR-Egger intercept = 0.0007, SE = 0.005, $P = 0.89$ and MR-PRESSO global test $P = 0.78$ for
14	UC; Supplementary Table S3).
15	
16	3.4 Two-sample Mendelian randomization analysis for the causality of ASD on IBD
17	The causal associations of ASD on IBD, including CD and UC, were evaluated. No evidence
18	of causal effects of ASD on IBD, CD, or UC were identified (Wald ratio [95% CI]: 1.04
19	[0.77-1.40], P = 0.80 for IBD; Wald ratio [95% CI]: 1.35 [0.92-1.99], P = 0.12 for CD; Wald

- 20 ratio [95% Cl]: 0.95 [0.65-1.39], *P* = 0.79 for UC; **Supplementary Table S4**).
- 21

22 4 Discussion

In the present study, we investigated the causal relationship between IBD and ASD using MR.
 Our findings indicate that genetic susceptibility to IBD, including both CD and UC, is
 associated with an increased risk of ASD, whereas genetic liability to ASD does not lead to
 IBD.

5 Previous observational studies suggest the comorbidity of IBD and ASD (Alexeeff et al., 6 2017; Butwicka et al., 2019; Doshi-Velez et al., 2015; Kohane et al., 2012; Lee et al., 2018). A 7 cross-sectional study involving over 14,000 patients with ASD indicates that the prevalence of 8 IBD among patients with ASD is higher than that in the overall hospital population (0.83% vs. 9 0.54%) (Kohane et al., 2012). A cohort study totaling over 60,000 ASD cases in the United 10 States demonstrates that the prevalence of IBD in patients with ASD is higher than that of the 11 control population or nationally reported rates (Doshi-Velez et al., 2015). In another 12 retrospective study from the TRICARE Management Activity Military Health System database 13 involving over 48,000 ASD cases, researchers identify an enhanced risk of IBD diagnosis in 14 children with ASD (OR = 1.67, 95% CI = 1.31-2.13) (Lee et al., 2018). A meta-analysis 15 involving over 11 million participants confirms that ASD is epidemiologically associated with 16 incident IBD (OR = 1.66, 95% CI = 1.25-2.21), including CD (OR = 1.47, 95% CI = 1.15-1.88) 17 and UC (OR = 1.91, 95%CI = 1.41-2.6) (Kim et al., 2022). Researchers assumed a temporal 18 order of IBD diagnosis subsequent to ASD diagnosis, indicating that ASD might increase the 19 risk of IBD (Kim et al., 2022). Among patients with IBD, based on a Northern California cohort, 20 it is observed that the risk of ASD is increased (odds ratio [OR] = 1.34, 95% confidence 21 interval [CI] = 1.22-1.40) (Alexeeff et al., 2017). A more recent study from a national Swedish 22 cohort demonstrates that patients with IBD is significantly associated with an increased risk of

developing ASD (hazard ratio [HR] = 1.40, 95% CI = 1.10-1.70) (Butwicka et al., 2019). By
 leveraging bi-directional MR design, our study reveals that the causality of ASD on IBD is
 unfounded. Instead, IBD could causally increase the risk of ASD.

4 The psychological status of patients with IBD has long been concerned, and plenty of 5 patients with IBD are comorbid with neuropsychological disorders (Gracie et al., 2019). In 6 current clinical guidelines for IBD from American College of Gastroenterology and British 7 Society of Gastroenterology, only screening for depression and anxiety is mentioned, and 8 psychological interventions for IBD patients are weakly recommended (Farraye et al., 2017; 9 Lamb et al., 2019). Although observational studies have indicated the association between 10 IBD with depression or schizophrenia, research by MR approaches eventually do not support 11 the causality of IBD on the two psychological disorders (Luo et al., 2022; Qian et al., 2022). In 12 contrast, our study suggests the causality of IBD on ASD, implying that awareness and 13 screening for ASD and other psychological disorders among patients with IBD are warranted. 14 Psychological supports and interventions might also be needed to help maintain the mental 15 health and improve the prognosis of patients with IBD.

The mean age of ASD diagnosis is 60.5 months, with a range from 30.9 to 234.6 months, according to a recent study involving 55 cohorts from 35 countries (van't Hof et al., 2021). For children with IBD, 4% and 18% of them present before age 5 and 10 years, receptively (Rosen et al., 2015). Patients with IBD, especially the children, often present with more insidious and non-specific symptoms, and can even be asymptomatic, which leads to common delays in the diagnosis of IBD (Ajbar et al., 2022; Rosen et al., 2015). Therefore, the significance of surveillance for ASD among patients with childhood-onset IBD is highlighted.

The ages at diagnosis of the populations with IBD or ASD used in this study are partially
 overlapped in childhood age, and the causal effects in our study might be underestimated
 since summary data based on age stratification is currently unavailable.

4 One strength of our study is that using the bi-directional two-sample MR approach, we 5 revealed the causality of IBD on ASD for the first time. Compared to previous observational 6 studies, our results are less affected by potential confounding, reverse causation, and other 7 biases that can generate their associations. Additionally, a series of sensitivity analyses were 8 conducted and confirmed that our results were robust. However, several limitations need to 9 be mentioned. Our research is limited to individuals of European ancestry, restricting the 10 generalizability of our conclusions to other ancestries. In addition, despite non-detected 11 heterogeneity and horizontal pleiotropy, the causal effect of UC on ASD was affected by 12 certain SNPs in the leave-one-out analysis, and therefore the findings in this study warrant 13 further validation by larger-scale and more powerful datasets. Moreover, subgroup analysis 14 stratified by the baseline characteristics, for example, age and sex, was not available due to 15 the use of summary-level statistics.

In summary, the present study reveals that genetically predicted IBD is causally related to ASD, whereas the causal association of ASD on IBD is not supported. Our study signifies the early screening and surveillance of psychological symptoms, as well as sustaining support for patients with IBD. Further explorations on age-stratified groups are warranted.

20

21 Data sharing statement

22 GWAS summary statistics are accessible from the original manuscript of each study in

1 **Supplementary Table 1**. Code used in this study is available from the corresponding authors

2 upon reasonable request.

3

4 **Conflict of Interest Statement**

- 5 The authors declared no conflict of interest.
- 6

7 Acknowledgement

8 This work is supported by the National Natural Science Foundation of China (82171698,

9 82170561, 81300279, 81741067, 82100238), the Natural Science Foundation for 10 Distinguished Young Scholars of Guangdong Province (2021B1515020003), the Guangdong 11 Basic and Applied Basic Research Foundation (2022A1515012081), the Climbing Program of 12 Introduced Talents and High-level Hospital Construction Project of Guangdong Provincial 13 People's Hospital (DFJH201923, DFJH201803, KJ012019099, KJ012021143, 14 KY012021183).

15

16 Author contributions

Conceptualization and design: HFT, WHS, HC; Administrative support: HFT, WHS, HC;
Funding acquisition: WHS, HC, JHW; Collection and assembly of data: RJZ, RJ, JHW; Data
analysis and interpretation: RJZ, RJ, JHW, JY, HHW, ZWZ, QY, JWL, SYL; Manuscript
writing-original draft: RJZ, RJ, JHW. Manuscript writing-review & editing: JY, HHW, ZWZ, QY,
JWL, KHG, SYL, HFT, WHS, HC. All authors reviewed and approved the final manuscript. All

- 1 authors had full access to all the data in the study and had final responsibility for the decision
- 2 to submit for publication.

1 References

- 2 Ajbar, A., Cross, E., Matoi, S., Hay, C.A., Baines, L.M., Saunders, B., Farmer, A.D., Prior, J.A.,
- 3 2022. Diagnostic Delay in Pediatric Inflammatory Bowel Disease: A Systematic Review.
- 4 Digestive Diseases and Sciences, 1-11.
- 5 Alexeeff, S.E., Yau, V., Qian, Y., Davignon, M., Lynch, F., Crawford, P., Davis, R., Croen, L.A.,
- 6 2017. Medical Conditions in the First Years of Life Associated with Future Diagnosis of ASD
- 7 in Children. J Autism Dev Disord 47, 2067-2079.
- 8 American Psychiatric Association, D., Association, A.P., 2013. Diagnostic and statistical
- 9 manual of mental disorders: DSM-5. American psychiatric association Washington, DC.
- 10 Argollo, M., Gilardi, D., Peyrin-Biroulet, C., Chabot, J.-F., Peyrin-Biroulet, L., Danese, S.,
- 2019. Comorbidities in inflammatory bowel disease: a call for action. The Lancet
 Gastroenterology & Hepatology 4, 643-654.
- 13 Bundgaard-Nielsen, C., Knudsen, J., Leutscher, P.D., Lauritsen, M.B., Nyegaard, M.,
- Hagstrøm, S., Sørensen, S., 2020. Gut microbiota profiles of autism spectrum disorder and
 attention deficit/hyperactivity disorder: A systematic literature review. Gut Microbes 11,
 1172-1187.
- Burgess, S., Butterworth, A., Thompson, S.G., 2013. Mendelian randomization analysis with
 multiple genetic variants using summarized data. Genet Epidemiol 37, 658-665.
- 19 Butwicka, A., Olén, O., Larsson, H., Halfvarson, J., Almqvist, C., Lichtenstein, P., Serlachius,
- 20 E., Frisén, L., Ludvigsson, J.F., 2019. Association of Childhood-Onset Inflammatory Bowel
- 21 Disease With Risk of Psychiatric Disorders and Suicide Attempt. JAMA Pediatr 173, 969-978.
- 22 Catalá-López, F., Hutton, B., Page, M.J., Driver, J.A., Ridao, M., Alonso-Arroyo, A., Valencia,

1	A., Macías Saint-Gerons, D., Tabarés-Seisdedos, R., 2022. Mortality in Persons With Autism							
2	Spectrum Disorder or Attention-Deficit/Hyperactivity Disorder: A Systematic Review and							
3	Meta-analysis. JAMA Pediatr 176, e216401.							
4	Davey Smith, G., Hemani, G., 2014. Mendelian randomization: genetic anchors for causal							
5	inference in epidemiological studies. Hum Mol Genet 23, R89-98.							
6	de Lange, K.M., Moutsianas, L., Lee, J.C., Lamb, C.A., Luo, Y., Kennedy, N.A., Jostins, L							
7	Rice, D.L., Gutierrez-Achury, J., Ji, S.G., Heap, G., Nimmo, E.R., Edwards, C., Henderson, F							
8	Mowat, C., Sanderson, J., Satsangi, J., Simmons, A., Wilson, D.C., Tremelling, M., Hart, A.,							
9	Mathew, C.G., Newman, W.G., Parkes, M., Lees, C.W., Uhlig, H., Hawkey, C., Prescott, N.J.,							
10	Ahmad, T., Mansfield, J.C., Anderson, C.A., Barrett, J.C., 2017. Genome-wide association							
11	study implicates immune activation of multiple integrin genes in inflammatory bowel disease.							
12	Nat Genet 49, 256-261.							
13	Doshi-Velez, F., Avillach, P., Palmer, N., Bousvaros, A., Ge, Y., Fox, K., Steinberg, G., Spettell							
14	C., Juster, I., Kohane, I., 2015. Prevalence of inflammatory bowel disease among patients							
15	with autism spectrum disorders. Inflammatory bowel diseases 21, 2281-2288.							
16	Fairbrass, K.M., Gracie, D.J., Ford, A.C., 2021. Longitudinal follow-up study: effect of							
17	psychological co-morbidity on the prognosis of inflammatory bowel disease. Alimentary							
18	Pharmacology & Therapeutics 54, 441-450.							
19	Farraye, F.A., Melmed, G.Y., Lichtenstein, G.R., Kane, S.V., 2017. ACG Clinical Guideline:							
20	Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol 112, 241-258.							
21	Gracie, D.J., Hamlin, P.J., Ford, A.C., 2019. The influence of the brain-gut axis in							
22	inflammatory bowel disease and possible implications for treatment. The Lancet							

1 Gastroenterology & Hepatology 4, 632-642.

2	Gracie, D.J., Williams, C.J., Sood, R., Mumtaz, S., Bholah, H.M., Hamlin, J.P., Ford, A.C.,
3	2016. Poor correlation between clinical disease activity and mucosal inflammation, and the
4	role of psychological comorbidity, in inflammatory bowel disease. Official journal of the
5	American College of Gastroenterology ACG 111, 541-551.
6	Graham, D.B., Xavier, R.J., 2020. Pathway paradigms revealed from the genetics of
7	inflammatory bowel disease. Nature 578, 527-539.
8	Grove, J., Ripke, S., Als, T.D., Mattheisen, M., Walters, R.K., Won, H., Pallesen, J., Agerbo,
9	E., Andreassen, O.A., Anney, R., Awashti, S., Belliveau, R., Bettella, F., Buxbaum, J.D.,
10	Bybjerg-Grauholm, J., Bækvad-Hansen, M., Cerrato, F., Chambert, K., Christensen, J.H.,
11	Churchhouse, C., Dellenvall, K., Demontis, D., De Rubeis, S., Devlin, B., Djurovic, S.,
12	Dumont, A.L., Goldstein, J.I., Hansen, C.S., Hauberg, M.E., Hollegaard, M.V., Hope, S.,
13	Howrigan, D.P., Huang, H., Hultman, C.M., Klei, L., Maller, J., Martin, J., Martin, A.R., Moran,
14	J.L., Nyegaard, M., Nærland, T., Palmer, D.S., Palotie, A., Pedersen, C.B., Pedersen, M.G.,
15	dPoterba, T., Poulsen, J.B., Pourcain, B.S., Qvist, P., Rehnström, K., Reichenberg, A.,
16	Reichert, J., Robinson, E.B., Roeder, K., Roussos, P., Saemundsen, E., Sandin, S.,
17	Satterstrom, F.K., Davey Smith, G., Stefansson, H., Steinberg, S., Stevens, C.R., Sullivan,
18	P.F., Turley, P., Walters, G.B., Xu, X., Stefansson, K., Geschwind, D.H., Nordentoft, M.,
19	Hougaard, D.M., Werge, T., Mors, O., Mortensen, P.B., Neale, B.M., Daly, M.J., Børglum, A.D.,
20	2019. Identification of common genetic risk variants for autism spectrum disorder. Nat Genet
21	51, 431-444.

22 Hemani, G., Zheng, J., Elsworth, B., Wade, K.H., Haberland, V., Baird, D., Laurin, C.,

1	Burgess, S., Bowden, J., Langdon, R., Tan, V.Y., Yarmolinsky, J., Shihab, H.A., Timpson, N.J.,
2	Evans, D.M., Relton, C., Martin, R.M., Davey Smith, G., Gaunt, T.R., Haycock, P.C., 2018.
3	The MR-Base platform supports systematic causal inference across the human phenome.
4	Elife 7.
5	Kaplan, G.G., Windsor, J.W., 2021. The four epidemiological stages in the global evolution of
6	inflammatory bowel disease. Nature reviews Gastroenterology & hepatology 18, 56-66.
7	Kim, J.Y., Choi, M.J., Ha, S., Hwang, J., Koyanagi, A., Dragioti, E., Radua, J., Smith, L.,
8	Jacob, L., de Pablo, G.S., 2022. Association between autism spectrum disorder and
9	inflammatory bowel disease: A systematic review and meta-analysis. Autism Research 15,
10	340-352.
11	Kohane, I.S., McMurry, A., Weber, G., MacFadden, D., Rappaport, L., Kunkel, L., Bickel, J.,
12	Wattanasin, N., Spence, S., Murphy, S., Churchill, S., 2012. The co-morbidity burden of
13	children and young adults with autism spectrum disorders. PLoS One 7, e33224.
14	Kõlves, K., Fitzgerald, C., Nordentoft, M., Wood, S.J., Erlangsen, A., 2021. Assessment of
15	Suicidal Behaviors Among Individuals With Autism Spectrum Disorder in Denmark. JAMA
16	Netw Open 4, e2033565.
17	Lamb, C.A., Kennedy, N.A., Raine, T., Hendy, P.A., Smith, P.J., Limdi, J.K., Hayee, B., Lomer,
18	M.C.E., Parkes, G.C., Selinger, C., Barrett, K.J., Davies, R.J., Bennett, C., Gittens, S., Dunlop,
19	M.G., Faiz, O., Fraser, A., Garrick, V., Johnston, P.D., Parkes, M., Sanderson, J., Terry, H.,
20	Gaya, D.R., Iqbal, T.H., Taylor, S.A., Smith, M., Brookes, M., Hansen, R., Hawthorne, A.B.,
21	2019. British Society of Gastroenterology consensus guidelines on the management of
22	inflammatory bowel disease in adults. Gut 68, s1-s106.

1	Lee, M., Krishnamurthy, J., Susi, A., Sullivan, C., Gorman, G.H., Hisle-Gorman, E.,						
2	Erdie-Lalena, C.R., Nylund, C.M., 2018. Association of autism spectrum disorders and						
3	inflammatory bowel disease. Journal of autism and developmental disorders 48, 1523-1529.						
4	Li, B., Martin, E.B., 2002. An approximation to the F distribution using the chi-square						
5	distribution. Computational statistics & data analysis 40, 21-26.						
6	Luo, J., Xu, Z., Noordam, R., van Heemst, D., Li-Gao, R., 2022. Depression and Inflammatory						
7	Bowel Disease: A Bidirectional Two-sample Mendelian Randomization Study. J Crohns						
8	Colitis 16, 633-642.						
9	Marini, S., Merino, J., Montgomery, B.E., Malik, R., Sudlow, C.L., Dichgans, M., Florez, J.C.,						
10	Rosand, J., Gill, D., Anderson, C.D., 2020. Mendelian randomization study of obesity and						
11	cerebrovascular disease. Annals of neurology 87, 516-524.						
12	Qian, L., He, X., Gao, F., Fan, Y., Zhao, B., Ma, Q., Yan, B., Wang, W., Ma, X., Yang, J., 2022.						
13	Estimation of the bidirectional relationship between schizophrenia and inflammatory bowel						
14	disease using the mendelian randomization approach. NPJ Schizophr 8, 31.						
15	Rosen, M.J., Dhawan, A., Saeed, S.A., 2015. Inflammatory bowel disease in children and						
16	adolescents. JAMA pediatrics 169, 1053-1060.						
17	Taylor, M.J., Rosenqvist, M.A., Larsson, H., Gillberg, C., D'Onofrio, B.M., Lichtenstein, P.,						
18	Lundström, S., 2020. Etiology of autism spectrum disorders and autistic traits over time.						
19	JAMA psychiatry 77, 936-943.						
20	van't Hof, M., Tisseur, C., van Berckelear-Onnes, I., van Nieuwenhuyzen, A., Daniels, A.M.,						
21	Deen, M., Hoek, H.W., Ester, W.A., 2021. Age at autism spectrum disorder diagnosis: A						
22	systematic review and meta-analysis from 2012 to 2019. Autism 25, 862-873.						

- 1 Verbanck, M., Chen, C.Y., Neale, B., Do, R., 2018. Detection of widespread horizontal
- 2 pleiotropy in causal relationships inferred from Mendelian randomization between complex
- 3 traits and diseases. Nat Genet 50, 693-698.
- Wan, Y., Zuo, T., Xu, Z., Zhang, F., Zhan, H., Dorothy, C., Leung, T.-F., Yeoh, Y.K., Chan, F.K.,
- 5 Chan, R., 2022. Underdevelopment of the gut microbiota and bacteria species as
- 6 non-invasive markers of prediction in children with autism spectrum disorder. Gut 71,
- 7 910-918.
- 8 Xu, G., Strathearn, L., Liu, B., Bao, W., 2018. Prevalence of autism spectrum disorder among
- 9 US children and adolescents, 2014-2016. Jama 319, 81-82.

1 Figure Legends

2	Figure 1. Schematic diagram of two-sample Mendelian randomization (MR) analysis for						
3	the causality between inflammatory bowel disease (IBD) and autism spectrum disorder						
4	(ASD). There are three core assumptions for MR: 1) Assumption 1: the instrumental variants						
5	(IVs) should be associated with the exposure (IBD); 2) Assumption 2: the IVs should not be						
6	associated with confounders; 3) Assumption 3: the IVs should influence the outcome (ASD)						
7	only by the exposure. The causal relationship between IBD and ASD will not be established if						
8	any of the assumptions are violated. ASD: autism spectrum disorder; IBD: inflammatory						
9	bowel disease; IIBDGC: International Inflammatory Bowel Disease Genetics Consortium;						
10	iPSYCH-PGC: Integrative Psychiatric Research-Psychiatric Genomics Consortium; IVW,						
11	inverse variance weighted; MR: Mendelian randomization; SNP, single-nucleotide						
12	polymorphism.						
13	Figure 2. The causal association of inflammatory bowel disease (IBD), including						
14	Crohn's disease (CD) and ulcerative colitis (UC), on autism spectrum disorder (ASD).						
15	Error bars indicate the 95% confidence intervals (CIs) for the estimates. CI: confidence						
16	interval; IVW: inverse variance weighted.						
17	Figure 3. Scatter plots of the causal association of inflammatory bowel disease (IBD),						
18	including Crohn's disease (CD) and ulcerative colitis (UC), on autism spectrum						
19	disorder (ASD). A. IBD on ASD; B. CD on ASD; C. UC on ASD. The slope of each line						
20	indicates the estimation of effects by each method. SNP: single nucleotide polymorphism.						

Figure 1



Figure 2

Exposure	Methods	SNPs		Odds Ratio (95% CI)	Р
Inflammatory Bowel Disease	IVW	101		1.03 (1.01-1.06)	0.01
	MR-Egger	101		1.05 (0.99-1.12)	0.12
	Weighted median	101		1.04 (0.99-1.08)	0.06
	Weighted mode	101		1.03 (0.97-1.11)	0.32
	MR-PRESSO	101		1.03 (1.01-1.06)	0.01
Crohn's Disease	IVW	75	-	1.03 (1.01-1.05)	0.02
	MR-Egger	75		1.02 (0.96-1.10)	0.50
	Weighted median	75		1.02 (0.99-1.06)	0.21
	Weighted mode	75	- _	1.01 (0.95-1.08)	0.66
	MR-PRESSO	75	-	1.03 (1.01-1.05)	0.02
Ulcerative Colitis	IVW	50	- -	1.03 (1.01-1.07)	0.04
	MR-Egger	50		1.07 (0.97-1.17)	0.17
	Weighted median	50		1.05 (1.01-1.10)	0.04
	Weighted mode	50		1.06 (0.99-1.13)	0.10
	MR-PRESSO	50	- -	1.03 (1.01-1.07)	0.04
			0.9 1.0 1.1 1.2 Odds Ratio	2	

Figure 3

А







			_	Mendelian randomization		Heterogeneity	
Exposure	Outcome	Method	SNPs	Odds ratio (95% CI)	Р	Q	Q_ <i>P</i>
IBD	ASD	IVW	101	1.03 (1.01-1.06)	0.01	98.10	0.53
		MR Egger	101	1.05 (0.99-1.12)	0.12	97.74	0.52
		Weighted median	101	1.04 (0.99-1.08)	0.06		
		Weighted mode	101	1.03 (0.97-1.11)	0.32		
		MR-PRESSO	101	1.03 (1.01-1.06)	0.01		
CD	ASD	IVW	75	1.03 (1.01-1.05)	0.02	64.43	0.78
		MR Egger	75	1.02 (0.96-1.10)	0.50	64.42	0.75
		Weighted median	75	1.02 (0.99-1.06)	0.21		
		Weighted mode	75	1.01 (0.95-1.08)	0.66		
		MR-PRESSO	75	1.03 (1.01-1.05)	0.02		
UC	ASD	IVW	50	1.03 (1.01-1.07)	0.04	62.25	0.08
		MR Egger	50	1.07 (0.97-1.17)	0.17	62.25	0.09
		Weighted median	50	1.05 (1.01-1.10)	0.04		
		Weighted mode	50	1.06 (0.99-1.13)	0.10		
		MR-PRESSO	50	1.03 (1.01-1.07)	0.04		

Table 1. Mendelian randomization (MR) analysis for the causality of inflammatory bowel diseases (IBD) on autism spectrum disorder (ASD).

ASD: autism spectrum disorder; CD: Crohn's disease; CI: confidence interval; IBD: inflammatory bowel disease; IVW: Inverse variance weighted; SNP: single-nucleotide polymorphism; UC: ulcerative colitis.